Premature ventricular complexes (PVCs) are extremely common arrhythmias. The majority of patients who underwent long-term ambulatory monitoring could be observed PVCs. One study have documented 35817 (0.2%) of 16.8 million California residents observed in hospitals, or outpatient centers between 2005 and 2009 had a healthcare code for a PVCs. All of increasing age, taller height, higher blood pressure, history of heart disease, less physical activity, and smoking are risk factors for greater PVC frequency. Although PVCs are commonly asymptomatic, can still produce dyspnea, palpitations, fatigue and presyncope. These troublesome symptoms will seriously disturb people's daily activities[4, 5]. Meanwhile，several previous studies have shown that patients with PVCs are associated with increased risk of cardiac mortality. In a multiracial community-based cohort study of >15 000 individuals, participants with PVCs on a 2-minute monitoring strip were >2 times as likely to die due to CHD than were those without PVCs. Currently, there are conflicts and challenges in prevention and management of PVCs. Some studies show reassurance is the most useful contribution that physician can provide when the burden of patients with PVCs is low. Patient often experience a worrisome sensation with their PVCs because they are concerned these symptoms may be a sign of something wrong or of some impending problem. And even in the presence of a normal LVEF, the symptoms of PVC still interfer their quality of life even after receiving that reassurance. Therefore, some patients will insist that their PVCs would be bothersome enough to try a medicine or a procedure, even if clinicians consider treatment should not necessarily be given for symptoms alone. For patients with PVCs associated with symptoms or a reduced left ventricular ejection fraction, β-blockers or class I or III anti-arrhythmic agents are considered effective medicines. However, treatment of PVCs with antiarrhythmic medications has not been shown to reduce mortality and, in the post-MI population, treatment with class I sodium channel–blocking medications increases the risk of death. In general, catheter ablation exhibits superior effectiveness, but may represent greater up-front risks. A small case series even found that ≈60% of all left ventricular ablations resulted in new brain emboli. Therefore, it is an important subject of PVCs treatment that seeking for a new effective and safe anti-arrhythmic method. Chinese Herbal medicine (CHM) is one of the most important content in Traditional Chinese medicine (TCM). Actually, CHM had been the dominantly medical approachs in China before Western medicine was introduced into the regions of chinese. Because of its advantages with respect to multiple targets, significant efficacy and safety, CHM has broad clinical prospects. With the development of basic and clinical studies on PVCs, CHM has shown its unique advantages in the treatment of PVCs. Several previous studies have shown CHM can effectively alleatue symptoms of heart palpitations, chest tightness, insomnia, fatigue in patients with PVCs[13, 14]. Mechanism of anti-arrhythmic effect might increase self-discipline and have blockade effect of different ion channels to shorten ventricular muscle cells action potential duration (APD). In the past years, many systematic reviews have been produced to evaluate the efficacy and safety of CHM for PVCs[15-18]. However, on the one hand, these studies only evaluated the therapeutic benefits of specific chinese herbal formula for PVCs. It is absence that comprehensively involve potential therapeutic benefits of CHM for PVCs and clearly demonstrate its potential mechanisms. On the other hand, the validity of a conclusion of systematic review is highly dependent on the quality of RCTs included. The low-quality RCTs with high risk of bias and high heterogenicity are misleading attribute to methodological flaws, which are not scientifically sound. Thus, there is still insufficient evidence to support routine use of CHMs for PVCs. The objective of the present study is to fully assess the existing evidence of CHM for PVCs after the exclusion of low-quality RCTs and explain the effective components and targets of CHM and the mechanisms of disease interaction.